** Citi finds improved sales momentum and positive operating cash flow in Bubs Australia's BUB.AX trading update
** Brokerage lifts price target to A$0.14 from A$0.13, maintains "neutral/high risk" rating
** Infant formula maker reported 1H25 EBITDA of A$2.9 mln ($1.82 mln) vs EBITDA loss of A$6.8 mln in the same period last year
** Citi sees co's FY25 rev guidance of A$102 mln to be achievable
** Brokerage, however, flags uncertainty around U.S. FDA approval and sustained positive cash flow as risks
** Stock up 20% so far this year as of last close
($1 = 1.5946 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。